{"id":202820,"date":"2024-12-30T20:24:09","date_gmt":"2024-12-31T02:24:09","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2024\/12\/traws-pharma-soars-as-it-advances-h5n1-bird-flu-treatment"},"modified":"2024-12-30T20:24:09","modified_gmt":"2024-12-31T02:24:09","slug":"traws-pharma-soars-as-it-advances-h5n1-bird-flu-treatment","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2024\/12\/traws-pharma-soars-as-it-advances-h5n1-bird-flu-treatment","title":{"rendered":"Traws Pharma soars as it advances H5N1 bird flu treatment"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/traws-pharma-soars-as-it-advances-h5n1-bird-flu-treatment.jpg\"><\/a><\/p>\n<p>USA-based clinical-stage biopharma Traws Pharma (Nasdaq: TRAW) saw its shares leap more than 150% to $12.57 as it announced progress in the development of its investigational one-dose influenza (flu) investigational therapy, tivoxavir marboxil for treatment of H5N1 bird flu. A Phase I trial tested tivoxavir marboxil in healthy adults who didn\u2019t have the flu.<\/p>\n<p>Traws Pharma expects to begin a Phase II study in the first half of 2025 as it expands its influenza program in response to the bird flu threat. The virus has been detected in dairy cattle in the USA. since March 2024, resulting in infections in over 60 people across eight states.<\/p>\n<p>\u201cThe spread of avian influenza in wild and domestic animal populations including mammals, brings increasing risk for adaptation to humans and subsequent spread in the population\u201d said Traws Pharma\u2019s chief medical officer Dr Robert Redfield, a former Director of the US Centers for Disease Control and Prevention (CDC). \u201cBird flu is an occupational hazard for poultry and dairy workers. With increasing numbers of human infections and recent reports of severe cases, we should be alert to the rising potential for epidemic or pandemic spread of bird flu,\u201d he added.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>USA-based clinical-stage biopharma Traws Pharma (Nasdaq: TRAW) saw its shares leap more than 150% to $12.57 as it announced progress in the development of its investigational one-dose influenza (flu) investigational therapy, tivoxavir marboxil for treatment of H5N1 bird flu. A Phase I trial tested tivoxavir marboxil in healthy adults who didn\u2019t have the flu. Traws [\u2026]<\/p>\n","protected":false},"author":534,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-202820","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/202820","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/534"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=202820"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/202820\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=202820"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=202820"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=202820"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}